Financial Data and Key Metrics - Revenue from existing business increased from $9.3 million to an annualized run rate of $16 million, with profits expected to be around $3.5 million [4] - Adjusted EBITDA and cash flow improved significantly in Q1 2024 compared to Q4 2023 [31] Business Line Data and Key Metrics - Pharmaloz is expected to see significant improvement in the second half of 2024, with full capacity demand for Q3 [26] - Nebula Genomics is projected to ramp up revenues in Q4 2024 or Q1 2025, with substantial potential in its bioinformatics platform and database [3][61] - Equivir, a dietary supplement, completed a study with over 300 patients, showing promising results in reducing illness from viruses like COVID, flu, and RSV [18][30] Market Data and Key Metrics - Pharmaloz has attracted potential new customers, including smaller brands that could fill up the second manufacturing line [6] - The BE-Smart Esophageal Cancer test targets a market of 7 million endoscopies annually, with potential insurance reimbursement of $1,000 to $2,000 per test, creating a $7 billion to $14 billion market [74] Company Strategy and Industry Competition - The company is exploring strategic alternatives for Pharmaloz, including potential sales or partnerships, after 1.5 to 2 years of planning and execution [5][29] - Nebula Genomics is developing a new go-to-market strategy leveraging social media and podcast experts, with potential celebrity endorsements [61][75] - The BE-Smart test is positioned as a breakthrough in cancer diagnostics, with no direct competition and multibillion-dollar potential [52][97] Management Commentary on Operating Environment and Future Outlook - Management believes the company is at a turning point, with significant developments expected in Pharmaloz, Nebula, and the BE-Smart test [28][40] - The company is focused on long-term value creation for shareholders, with no immediate plans for equity financing [23][103] - The lab infrastructure for Nebula Genomics is seen as a strategic asset, despite current costs, due to its potential for future growth [51][110] Other Important Information - The company has a history of successful turnarounds, including the sale of Cold-EEZE for $50 million and IT Biomedical for $1.4 billion [63] - The AI initiative leverages the company’s database and proprietary discoveries, focusing on anti-drug conjugates for cancer treatment [78] Q&A Session Question: Growth plans for Nebula Genomics - Nebula’s growth strategy includes leveraging its bioinformatics platform, database, and social media experts, with revenues expected to ramp up in Q4 2024 or Q1 2025 [61][75][116] Question: Potential IPO for Nebula or Pharmaloz - The company is open to IPOs for Nebula or Pharmaloz under the right market conditions but is cautious about timing to maximize valuation [22][109] Question: Revenue expectations for Q2 2024 - Management does not expect significant revenue growth in Q2, with major improvements anticipated in Q3 for Pharmaloz and Q4 for Nebula [31][87] Question: Claims for Equivir packaging - Claims for Equivir are still being finalized, with the company planning to launch the product online first before expanding to retail stores [86][118] Question: Valuation of CDMO sales licensing transactions - The company declined to provide additional information on CDMO valuation, citing ongoing strategic discussions [24] Question: Potential partnership for BE-Smart - The company is open to exploring partnerships for BE-Smart but is focused on maximizing long-term shareholder value [32][36] Question: Share count increase from 18 million to 90 million - Management did not provide specific details on the share count increase, only noting that shares change over time [111]

Exhibit 99.1 ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test. The shortage of lozenge manufacturing capacity that the Company has previou ...

Table of Contents Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Delaware 23-2577138 ...

FORWARD LOOKING STATEMENT ProPhaseLabs.com NASDAQ: PRPH Before we get started, I would like to remind you of the company's Safe Harbor language. During this presentation, we will make forward- looking statements, including statements regarding our strategies, plans, objectives and initiatives and underlying assumptions. While we believe that these forward-looking statements are reasonable as and when made, forward-looking statements are based on expectations that involve risks and uncertainties that could c ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Conference Call March 15, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs' Fourth Quarter and Ye ...

Exhibit 99.1 ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 Delaware 23-2577138 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update. All participants will be in listen-only mode. [Operator Instructions] After today's present ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Dennis Waldman - Barrett Productions Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Second Quarter 2023 Financial Results and Corporate Update. All participants’ will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ...

For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) | Delaware | 23-2577138 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | | of inc ...